PALB2 and ovarian cancer: Based on the studies in breast and ovarian cancer, BRCAness are present in about 20% of breast cancer and 45% of ovarian cancer [17,18], such as the mutations in RAD51C, NBS1, BRIP1, and PALB2 [19].